A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 5 of 12 entries
    • Site details revised at 11 of 11 sites
  2. Site details revised at 5 of 11 sitesv6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 11 of 11 sites
    v5
  4. Re-verified, no change to tracked fieldsv4
  5. Start date: Mar 15, 2025 to Jun 15, 2025
    • Study sites: 5 to 11
    • Primary completion date: Dec 15, 2026 to Dec 30, 2026
    v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.
Trial Details
NCT Number NCT06830850
Lead Sponsor Atridia Pty Ltd.
Conditions
(from sponsor)		 Metastatic Castration Resistant Prostate Cancer
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov